Gain Therapeutics, Inc. Annual Report - How They Did This Year

I am writing this guide to help you understand Gain Therapeutics’ performance this year. My goal is to turn complex filings into clear information to help you decide if this company fits your investment goals.

1. What does this company do and how did they perform?

Gain Therapeutics is a biotech company using its "Magellan™" AI platform to find new ways to treat diseases. They focus on "protein misfolding," where proteins fail to form the right shapes. This causes brain diseases like Parkinson’s, Gaucher, and Krabbe disease.

Their main project is GT-02287. Unlike treatments that just manage symptoms, this drug acts as a "chaperone" to stabilize enzymes and restore brain function. They finished two safety studies in healthy volunteers. Now, they are running a Phase 1b trial for patients with GBA1-mutated Parkinson’s. By late 2025, 21 patients had enrolled. Most chose to continue the treatment, which suggests the drug is safe and patients see value in it.

2. Financial performance

Gain Therapeutics does not sell products yet, so it has no sales revenue. The company loses money because it spends heavily on research and development (R&D). In 2025, they spent about $18.4 million on clinical trials and platform maintenance.

As of February 2026, they had 42.2 million shares outstanding. The company funds its work by selling stock. In June 2025, the market value of shares held by the public was about $53.2 million, based on a stock price of $1.26.

3. Major wins and challenges

• Wins: Moving GT-02287 into patient trials is a major milestone. Also, tests show the drug successfully crosses the blood-brain barrier. This is a difficult technical hurdle that stops many other brain-focused drugs.
• Challenges: The company spends between $1.2 million and $1.5 million per month. Because they have no products to sell, they rely entirely on outside investors or partners to keep the lights on.

4. Financial health

The company needs more money to keep operating. They had about $12.8 million in cash as of their last report. Management expects they will need additional funding within the next 12 months. They are actively looking for partnerships with larger drug companies to help cover costs without relying solely on selling more stock.

5. Key risks

• Clinical Success: The company’s value depends almost entirely on GT-02287. If upcoming 2026 data shows the drug does not work or is unsafe, the stock price could drop significantly.
• Competition: Gain competes with massive pharmaceutical companies. These rivals have much larger budgets and established teams to bring drugs to market.
• Dilution: To raise cash, the company may need to issue more shares. This reduces your ownership percentage and the value of your existing shares.

Final Thought for Investors: Gain Therapeutics is a high-risk, high-reward play. Because they are in the early stages of clinical trials and currently lack the cash to fund operations for the long term, your investment is essentially a bet on the success of their GT-02287 drug. Keep a close eye on their upcoming clinical data and any announcements regarding partnerships, as these will be the primary drivers of the company's future value.